Quick Answer
Jade Biosciences, Inc. reported R&D Expense of $93.12 million for fiscal year 2025.
Jade Biosciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $93.12M | +75.1% |
| 2024 | $53.19M | -17.2% |
| 2023 | $64.22M | +66.3% |
| 2022 | $38.62M | +157.7% |
| 2021 | $14.99M | +88.8% |
| 2020 | $7.94M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $22.01M | +62.1% | -2.4% |
| June 30, 2025 | $22.55M | +28806.4% | +66.0% |
| September 30, 2024 | $13.58M | -19.6% | +17311.5% |
| June 30, 2024 | $78.0K | -99.5% | -99.6% |
| March 31, 2024 | $20.08M | +48.9% | +18.9% |
| September 30, 2023 | $16.88M | +56.6% | +5.3% |
| June 30, 2023 | $16.03M | +91.7% | +18.9% |
| March 31, 2023 | $13.49M | +85.9% | +25.1% |
- Jade Biosciences, Inc. showed an increase of +75.1% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Jade Biosciences, Inc.’s r&d expense has grown by 1072.8% (from $7.94 million to $93.12 million).
- The most recent figure is from Jade Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: